Shots:
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency  
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients  
A major highlight was the EC’s approval of Sandoz’ Afqlir for treating…
